|
|
| Line 4: |
Line 4: |
| {{CMG}}; {{AE}} {{ARK}} | | {{CMG}}; {{AE}} {{ARK}} |
| ==Overview== | | ==Overview== |
| There is insufficient evidence to recommend routine screening for Struma ovarii. However, in cases of metastatic struma ovarii post total [[thyroidectomy]] along with [[radioiodine]]<nowiki/> scanning and radioiodine ablation, the [[thyroglobulin]] levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease. | | There is insufficient evidence to recommend routine screening for Struma ovarii. |
|
| |
|
| ==Screening== | | ==Screening== |
|
| |
|
| *There is insufficient evidence to recommend routine screening for Struma ovarii. | | *There is insufficient evidence to recommend routine screening for Struma ovarii. |
| *For follow-up as a marker of recurrence, serum thyroglobulin levels and [[Iodine-131|I-131]] scan may be used. <ref name="pmid12821363">{{cite journal |vauthors=Volpi E, Ferrero A, Nasi PG, Sismondi P |title=Malignant struma ovarii: a case report of laparoscopic management |journal=Gynecol. Oncol. |volume=90 |issue=1 |pages=191–4 |year=2003 |pmid=12821363 |doi= |url=}}</ref> <ref name="pmid17168212">{{cite journal |vauthors=Zekri JM, Manifold IH, Wadsley JC |title=Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments |journal=Clin Oncol (R Coll Radiol) |volume=18 |issue=10 |pages=768–72 |year=2006 |pmid=17168212 |doi= |url=}}</ref> <ref name="pmid24783110">{{cite journal |vauthors=Sinha NK |title=Struma ovarii with elevated ca-125 levels and ascites mimicking advanced ca ovary |journal=J Clin Diagn Res |volume=8 |issue=3 |pages=140–1 |year=2014 |pmid=24783110 |pmc=4003614 |doi=10.7860/JCDR/2014/8005.4138 |url=}}</ref>
| |
| *The I-131 scan or [[thyroglobulin]] have no aid in the follow-up if [[thyroidectomy]] is not performed. <ref name="pmid15963556">{{cite journal |vauthors=Balci TA, Kabasakal L |title=Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy? |journal=Gynecol. Oncol. |volume=99 |issue=2 |pages=520 |year=2005 |pmid=15963556 |doi=10.1016/j.ygyno.2005.04.017 |url=}}</ref>
| |
| *In cases of [[metastatic]] struma ovarii post total [[thyroidectomy]] along with [[radioiodine]] scanning and radioiodine ablation, the [[thyroglobulin]] levels must be monitored as a [[tumor marker]], and diagnostic [[radioiodine]] scans should be done to screen for [[residual]] or recurrent disease. <ref name="pmid19289330">{{cite journal| author=McGill JF, Sturgeon C, Angelos P| title=Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation. | journal=Endocr Pract | year= 2009 | volume= 15 | issue= 2 | pages= 167-73 | pmid=19289330 | doi=10.4158/EP.15.2.167 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19289330 }} </ref>
| |
|
| |
|
| ==References== | | ==References== |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
There is insufficient evidence to recommend routine screening for Struma ovarii.
Screening
- There is insufficient evidence to recommend routine screening for Struma ovarii.
References
Template:WH
Template:WS